Sandra P D'angelo

List of Publications by Year
in descending order

73	12,787	172457 29	128289 60
papers	citations	h-index	g-index

74	74	74	17768
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical Resection. Annals of Surgical Oncology, 2022, 29, 640-648.	1.5	17
2	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
3	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3
4	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. , 2022, 10, e003302.		16
5	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
6	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. Clinical Cancer Research, 2022, 28, 939-947.	7.0	10
7	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	12.8	63
8	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nature Communications, 2022, 13, .	12.8	21
9	Immunotherapy in Sarcoma. Surgical Oncology Clinics of North America, 2022, 31, 381-397.	1.5	9
10	Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches. Touch Reviews in Oncology & Haematology, 2022, 18, 73.	0.2	0
11	The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 834-844.	4.9	11
12	Selinexor, a First in Class, Nuclear Export Inhibitor for the Treatment of Advanced Malignant Peripheral Nerve Sheath Tumor. Oncologist, 2021, 26, e710-e714.	3.7	3
13	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel) Tj ETQq1 1 0.784314 rgBT /Ov		32
14	The impact of MYC gene amplification on the clinicopathological features and prognosis of radiationâ€associated angiosarcomas of the breast. Histopathology, 2021, 79, 836-846.	2.9	9
15	Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases. Frontiers in Oncology, 2021, 11, 725484.	2.8	4
16	Efficacy and immune-related adverse event associations in avelumab-treated patients. , 2020, 8, e001427.		16
17	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clinical Cancer Research, 2020, 26, 5448-5455.	7.0	12
18	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncology, 2020, 16, 2089-2099.	2.4	2

#	Article	IF	Citations
19	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	3.0	18
20	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. , 2020, 8, e000674.		132
21	Patient Experiences with Avelumab in Treatment-NaÃ¯ve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. Patient, 2020, 13, 457-467.	2.7	11
22	Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. Sarcoma, 2020, 2020, 1-8.	1.3	2
23	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. JAMA Oncology, 2020, 6, 402.	7.1	125
24	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 2019, 37, 282-290.	2.6	32
25	Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. , 2019, 7, 276.		101
26	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 609-618.	4.2	21
27	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
28	Immune Checkpoint Inhibitors in Sarcoma. , 2019, , 125-137.		0
29	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncology, The, 2018, 19, 416-426.	10.7	517
30	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. JAMA Oncology, 2018, 4, e180077.	7.1	304
31	Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. OncoImmunology, 2018, 7, e1372081.	4.6	37
32	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after â‰¥1Âyear of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
33	Cytokine release syndrome after radiation therapy: case report and review of the literature. , 2018, 6, 1.		54
34	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discovery, 2018, 8, 944-957.	9.4	313
35	18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. Journal of Clinical Oncology, 2018, 36, 192-192.	1.6	11
36	Association between objective responses (OR) and overall survival (OS) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab.. Journal of Clinical Oncology, 2018, 36, 193-193.	1.6	3

#	Article	IF	Citations
37	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 226-235.	1.6	458
38	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 319-330.e1.	0.8	96
39	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	7.0	106
40	Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?. Annals of Thoracic Surgery, 2017, 104, 1837-1845.	1.3	28
41	Impact of next-generation sequencing (NGS) on diagnostic and therapeutic options in soft-tissue and bone sarcoma.. Journal of Clinical Oncology, 2017, 35, 11001-11001.	1.6	26
42	A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401).. Journal of Clinical Oncology, 2017, 35, 11007-11007.	1.6	26
43	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. Journal of Clinical Oncology, 2017, 35, 11008-11008.	1.6	32
44	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2017, 35, 11010-11010.	1.6	3
45	Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1^{c259}t in HLA-A2⁺ patients with synovial sarcoma (NCT01343043).. Journal of Clinical Oncology, 2017, 35, 3000-3000.	1.6	20
46	First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study.. Journal of Clinical Oncology, 2017, 35, 9530-9530.	1.6	10
47	A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).. Journal of Clinical Oncology, 2017, 35, TPS3097-TPS3097.	1.6	1
48	Risk factors associated with ifosfamide (IFOS)-induced encephalopathy in patients (pts) with metastatic (Met) sarcoma (Sarc).. Journal of Clinical Oncology, 2017, 35, e22518-e22518.	1.6	1
49	A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2017, 35, 11039-11039.	1.6	0
50	Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e558-e564.	3.8	8
51	Reply to A. Indini et al. Journal of Clinical Oncology, 2016, 34, 1018-1019.	1.6	0
52	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunology Research, 2016, 4, 383-389.	3.4	247
53	Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib. JAMA Oncology, 2016, 2, 937.	7.1	241
54	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 1374-1385.	10.7	1,034

#	Article	IF	Citations
55	Current status of engineered T-cell therapy for synovial sarcoma. Immunotherapy, 2016, 8, 1073-1080.	2.0	15
56	Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Journal of Clinical Oncology, 2016, 34, 3166-3174.	1.6	133
57	Outcomes of Systemic Therapy for Patients with Metastatic Angiosarcoma. Oncology, 2015, 89, 205-214.	1.9	38
58	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Human Pathology, 2015, 46, 357-365.	2.0	252
59	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology, The, 2015, 16, 375-384.	10.7	2,353
60	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. Oncologist, 2015, 20, 1245-1246.	3.7	25
61	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology, 2015, 33, 3193-3198.	1.6	892
62	Abstract 4707: Genetically engineered NY-ESO-1-specific T cells in HLA-A2+ patients with synovial sarcoma. , 2015, , .		2
63	A phase Ib/II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2015, 33, 10507-10507.	1.6	16
64	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1118-1127.	3.7	131
65	Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation. Clinical Lung Cancer, 2014, 15, 405-410.	2.6	63
66	Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With AdvancedCDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma. Journal of Clinical Oncology, 2013, 31, 2024-2028.	1.6	370
67	Ipilimumab for Patients With Advanced Mucosal Melanoma. Oncologist, 2013, 18, 726-732.	3.7	140
68	Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers. Clinical Cancer Research, 2012, 18, 6169-6177.	7.0	503
69	Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib. Journal of Thoracic Oncology, 2012, 7, 1815-1822.	1.1	160
70	Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. Journal of Thoracic Oncology, 2011, 6, 569-575.	1.1	124
71	A Case Series of Dose-Limiting Peripheral Edema Observed in Patients Treated with Pemetrexed. Journal of Thoracic Oncology, 2011, 6, 624-626.	1.1	18
72	Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: Report on initial experience and clinical utility at a single center. Journal of Thoracic and Cardiovascular Surgery, 2011, 141, 476-480.	0.8	40

#	Article	IF	Citations
73	Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas. Journal of Clinical Oncology, 2011, 29, 2066-2070.	1.6	247